Hospital San Jose
- Address
- lock Available on a paid plan
Congenital, Hereditary, and Neonatal Diseases
Hospital San Jose’s pediatric unit is advancing care for children with achondroplasia and related growth disorders, testing innovative medicines aimed at increasing height potential. The trials also explore treatments for hypochondroplasia to improve stature and quality of life.
- Evaluation of growth‑enhancing agents
- Assessment of safety and tolerability in young patients
- Comparison of novel therapies against standard care
These efforts position the site as a leading center for rare skeletal disease research in Europe.
Musculoskeletal Diseases
Focused on pediatric skeletal dysplasia, the research at the hospital investigates how new compounds can support bone development in children with achondroplasia. The goal is to provide effective solutions for short stature linked to musculoskeletal abnormalities.
- Bone lengthening strategies
- Functional outcome measurements
- Longitudinal growth tracking
Findings are expected to inform clinical guidelines for managing musculoskeletal conditions in children.
Genetic Phenomena
The program examines the genetic mechanisms behind dwarfing conditions, targeting the FGFR3 pathway with precision medicines. By linking genotype to therapeutic response, researchers aim to personalize treatment for affected youths.
- Molecular inhibition studies
- Genotype‑phenotype correlation analysis
- Biomarker identification for treatment response
Collaboration with international genetics labs enhances the scientific impact of the work conducted at Hospital San Jose.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Qed Therapeutics Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Qed Therapeutics Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital San Jose
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Infigratinib in Pediatric Patients with Hypochondroplasia: A Phase 2/3 Multicenter, Open-Label and Double-Blind, Placebo-Controlled Study | Qed Therapeutics Inc. | Phase IV | Recruiting | Aug 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Infigratinib | 2 | Unknown | 2024-08-20 | 2025-08-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.